Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!
Measuring ResMed Inc.'s (NYSE:RMD) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, which is a powerful signal for future performance. Below, I will assess RMD's recent performance announced on 31 March 2019 and compare these figures to its historical trend and industry movements.
How Well Did RMD Perform?
RMD's trailing twelve-month earnings (from 31 March 2019) of US$446m has jumped 45% compared to the previous year.
Furthermore, this one-year growth rate has exceeded its 5-year annual growth average of 1.5%, indicating the rate at which RMD is growing has accelerated. How has it been able to do this? Let's take a look at if it is merely due to industry tailwinds, or if ResMed has seen some company-specific growth.
In terms of returns from investment, ResMed has invested its equity funds well leading to a 22% return on equity (ROE), above the sensible minimum of 20%. Furthermore, its return on assets (ROA) of 11% exceeds the US Medical Equipment industry of 6.8%, indicating ResMed has used its assets more efficiently. However, its return on capital (ROC), which also accounts for ResMed’s debt level, has declined over the past 3 years from 19% to 17%. This correlates with an increase in debt holding, with debt-to-equity ratio rising from 23% to 66% over the past 5 years.
What does this mean?
ResMed's track record can be a valuable insight into its earnings performance, but it certainly doesn't tell the whole story. Positive growth and profitability are what investors like to see in a company’s track record, but how do we properly assess sustainability? I suggest you continue to research ResMed to get a better picture of the stock by looking at:
- Future Outlook: What are well-informed industry analysts predicting for RMD’s future growth? Take a look at our free research report of analyst consensus for RMD’s outlook.
- Financial Health: Are RMD’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
- Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
NB: Figures in this article are calculated using data from the trailing twelve months from 31 March 2019. This may not be consistent with full year annual report figures.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.